Opinion|Videos|April 11, 2025
Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis
Panelists discuss how when prescribing an IL-17 inhibitor, key safety considerations include infection risk (particularly tuberculosis and fungal infections), inflammatory bowel disease exacerbation, allergic reactions, neutropenia, immunogenicity, vaccination timing, pregnancy/breastfeeding status, malignancy history, and monitoring requirements for adverse events.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What safety data do you take into consideration when prescribing an IL-17 inhibitor?
Advertisement
Related to this article
Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.
Takeda’s investigational oral TYK2 inhibitor is supported by phase 3 LATITUDE data demonstrating significant skin clearance versus placebo and apremilast.
In a 52-week open-label trial, tildrakizumab-asmn (Ilumya) reduced a mortality-linked DNA methylation clock by up to 0.5 years while clearing psoriasis symptoms.
Advertisement
Advertisement
Trending on Dermatology Times
1
FAQ: Everything Clinicians (and Their Patients) Want to Know About the Hair Loss Pipeline
2
Barzolvolimab Achieves All Phase 3 End Points in Chronic Spontaneous Urticaria
3
ORKA-001 Achieves Deepening Skin Clearance Through Week 28 in Plaque Psoriasis
4
National APP Week: Donna Lam Cahill, PA-C, on Persistence, Patient Advocacy, and Finding a Career in Dermatology
5